PACT Pharma Announces Agreement to Sell Select Assets to AmplifyBio

PACT to Retain Core R&D Capabilities and Continue Development of Novel, Neoantigen-Targeted T Cell Therapies AmplifyBio to Leverage Newly Acquired Assets to Enhance Cell and Gene Therapy Characterization Capabilities SOUTH SAN FRANCISCO, Calif., Sept. 30, 2022 /PRNewswire/ — PACT Pharma,…